Isatina, un compuesto endógeno a considerar en la Enfermedad de Parkinson

Lorenzo A. Justo-Cousiño; Lilian Faro; Rafael Durán

doi:10.35839/repis.5.2.928

Autores/as

Lorenzo A. Justo-Cousiño Universidad de Vigo, Pontevedra, España https://orcid.org/0000-0002-1787-4017
Lilian Faro Universidad de Vigo, Pontevedra, España
Rafael Durán Universidad de Vigo, Pontevedra, España

DOI:

https://doi.org/10.35839/repis.5.2.928

Resumen

Descargas

Los datos de descarga aún no están disponibles.

Biografía del autor/a

Lorenzo A. Justo-Cousiño, Universidad de Vigo, Pontevedra, España

Dr. Lorenzo Antonio Justo Cousiño. Neuroscience PhD.
- Departamento de Biología Funcional y Ciencias de la Salud. Universidad de Vigo, Pontevedra,
España.
-Colaborador Laboratorio de Neuroquímica de la Universidad de Vigo. Campus Lagoas-
Marcosende, 36310, Vigo, España.
Datos de contacto:
Lorenzo A. Justo Cousiño: lorenzo.antonio.justo@gmail.com
Dirección postal:
Dr. Lorenzo Antonio Justo Cousiño. Facultad de Fisioterapia. Universidad de Vigo. Campus A Xunqueira
s/n, 36005 Pontevedra. Galicia. España. Teléfono: (+34) 986 801 750.

Referencias

Hamaue N, Minami M, Terado M, Hirafuji M, Endo T, Machida M, et al. Comparative Study of the Effects of Isatin, an Endogenous MAO-Inhibitor, and Selegiline on Bradykinesia and Dopamine Levels in a Rat Model of Parkinson’s Disease Induced by the Japanese Encephalitis Virus. Neurotoxicology. 2004; 25(1-2): 205-13.

Xu H, Wang D, Zhang W, Zhu W, Yamamoto K, Jin L. Determination of isatin and monoamine neurotransmitters in rat brain with liquid chromatography using palladium hexacyanoferrate modified electrode. Anal Chim Acta. 2006; 577(2): 207-13.

Justo LA, Durán R, Alfonso M, Fajardo D, Faro LRF. Effects and mechanism of action of isatin, a MAO inhibitor, on in vivo striatal dopamine release. Neurochem Int. 2016; 99: 147-57.

Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J Neural Transm. 2018; 125(11): 1735-49.

Hamaue N. Pharmacological Role of Isatin, an Endogenous MAO Inhibitor. Yakugaku Zasshi. 2000; 120(4): 352-62.

Buneeva O, Medvedeva M, Kopylov A, Medvedev A. Ubiquitin Subproteome of Brain Mitochondria and Its Changes Induced by Experimental Parkinsonism and Action of Neuroprotectors. Biochemistry Mosc. 2019; 84(11): 1359-74.

Medvedev A, Kopylov A, Buneeva O, Kurbatov L, Tikhonova O, Ivanov A, et al. A Neuroprotective Dose of Isatin Causes Multilevel Changes Involving the Brain Proteome: Prospects for Further Research. Int J Mol Sci. 2020; 21(11): 4187.

Zhang J, Zhang F, Qiu Y, Yue W. Isatin decreases Bax protein expression in the substantia nigra of a mouse model of Parkinson’s disease. Neural Regen Res. 2011; 6(26): 2022-5.

Buneeva OA, Kapitsa IG, Ivanova EA, Kopylov AT, Zgoda VG, Medvedev AE. The effect of a neuroprotective dose of isatin or deprenyl to mice on the profile of brain isatin-binding proteins. Biochem Mosc Suppl B Biomed Chem. 2020; 14(2): 116-26.

Faro LRF, Justo LA, Alfonso M, Durán R. Possible synergies between isatin, an endogenous MAO inhibitor, and antiparkinsonian agents on the dopamine release from striatum of freely moving rats. Neuropharmacology. 2020; 171:108083.